Literature DB >> 26618995

Persistence of Yellow Fever vaccine-induced antibodies after cord blood stem cell transplant.

Vivian Iida Avelino-Silva1,2, Marcos da Silva Freire3, Vanderson Rocha2, Celso Arrais Rodrigues2, Yana Sarkis Novis2, Ester C Sabino1,4, Esper Georges Kallas1,2,5.   

Abstract

We report the case of a cord blood haematopoietic stem cell transplant recipient who was vaccinated for Yellow Fever (YF) 7 days before initiating chemotherapy and had persistent YF antibodies more than 3 years after vaccination. Since the stem cell donor was never exposed to wild YF or to the YF vaccine, and our patient was not exposed to YF or revaccinated, this finding strongly suggests the persistence of recipient immunity. We briefly discuss potential consequences of incomplete elimination of recipient's leukocytes following existing haematopoietic cancer treatments.

Entities:  

Keywords:  cord blood stem cell transplant; immunosuppression; vaccine; yellow fever

Mesh：

Substances：

Year:  2015        PMID： 26618995      PMCID： PMC4962932          DOI： 10.1080/21645515.2015.1112475

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  10 in total

1.  Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.

Authors:  V Spoulou; M Giannaki; M Vounatsou; C Bakoula; S Grafakos
Journal:  Bone Marrow Transplant       Date:  2004-06       Impact factor: 5.483

Review 2.  Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?

Authors:  Alan D T Barrett; Dirk E Teuwen
Journal:  Curr Opin Immunol       Date:  2009-06-10       Impact factor: 7.486

3.  Vaccination of hematopoietic cell transplant recipients.

Authors:  P Ljungman; C Cordonnier; H Einsele; J Englund; C M Machado; J Storek; T Small
Journal:  Bone Marrow Transplant       Date:  2009-10       Impact factor: 5.483

4.  Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies.

Authors:  Marisol Simões; Luiz Antonio B Camacho; Anna M Y Yamamura; Emily Hime Miranda; Ana Carolina R A Cajaraville; Marcos da Silva Freire
Journal:  Biologicals       Date:  2012-09-30       Impact factor: 1.856

5.  Yellow fever vaccine viremia following ablative BM suppression in AML.

Authors:  V I Avelino-Silva; F E Leal; E C Sabino; A S Nishiya; M da Silva Freire; F Blumm; V Rocha; C A Rodrigues; Y S Novis; E G Kallas
Journal:  Bone Marrow Transplant       Date:  2013-01-21       Impact factor: 5.483

6.  A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT.

Authors:  T Parkkali; R M Olander; T Ruutu; K Vuontela; L Volin; J Eskola; P Ruutu
Journal:  Bone Marrow Transplant       Date:  1997-05       Impact factor: 5.483

7.  Loss of protective immunity to polio, diphtheria and Haemophilus influenzae type b after allogeneic bone marrow transplantation.

Authors:  T Parkkali; T Ruutu; M Stenvik; T Kuronen; H Käyhty; T Hovi; R M Olander; L Volin; P Ruutu
Journal:  APMIS       Date:  1996-05       Impact factor: 3.205

Review 8.  Yellow fever: an update.

Authors:  T P Monath
Journal:  Lancet Infect Dis       Date:  2001-08       Impact factor: 25.071

9.  Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.

Authors:  Rita B Effros; Courtney V Fletcher; Kelly Gebo; Jeffrey B Halter; William R Hazzard; Frances McFarland Horne; Robin E Huebner; Edward N Janoff; Amy C Justice; Daniel Kuritzkes; Susan G Nayfield; Susan F Plaeger; Kenneth E Schmader; John R Ashworth; Christine Campanelli; Charles P Clayton; Beth Rada; Nancy F Woolard; Kevin P High
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

10.  Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.

Authors:  B Reinhardt; R Jaspert; M Niedrig; C Kostner; J L'age-Stehr
Journal:  J Med Virol       Date:  1998-10       Impact factor: 2.327
  10 in total
  1 in total

1. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.